Skip to main content
SpringerLink
Log in

Association of COX-2 rs20417 with aspirin resistance

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably stroke and myocardial infarction. However, despite the demonstrated benefit of aspirin, significant fraction of aspirin-treated patients may be resistant to the antiplatelet effects of the drug. The possible mechanisms of aspirin resistance (AR) are multifactorial. A genetic basis for AR has been suggested to exist. Therefore, the present study was taken up to investigate the role of −765G/C polymorphism (rs20417) in the cyclooxygenase-2 (COX-2) gene with AR in stroke patients. Four hundred and fifty stroke patients and four hundred and forty age and sex matched healthy controls were involved in the study. Baseline clinical data were collected and follow-up telephone interviews were conducted with patients at 3 months post event to determine stroke outcome using Modified Rankin Scale. Blood samples were collected and genotypes determined by polymerase chain reaction-restriction digestion technique. The association between the genotypes and outcome was evaluated by stepwise multiple logistic regression analysis. The COX-2 CC and GC genotype showed a significant association with bad outcome. Therefore, the carriers of C allele of COX-2 −765G/C polymorphism are more prone to AR in comparison with non-carriers. These results support a potential role of −765G/C COX-2 gene polymorphism with AR in ischemic stroke patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Antithromobotic Trialists Collaboration (2002) Collaboration meta analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324:71–86

    Article  Google Scholar 

  2. Nutiu R, Bolcu C, Modra D, Albulescu M, Lagher R, Heiman C (2003) Practice in organic chemistry, vol 2 (in Romania). Eurostampa Publishing House, Timisoara, p 37

    Google Scholar 

  3. Patrono C, Baigent C, Hirsh J, Roth G, American College of Chest Physicians (2008) Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6):199S–233S

    Article  PubMed  CAS  Google Scholar 

  4. Wang D, Mann JR, Du Bois RN (2005) The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128(5):1445–1461

    Article  PubMed  CAS  Google Scholar 

  5. Patrono C, Coller B, Fitz-Gerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3):234S–264S

    Article  PubMed  CAS  Google Scholar 

  6. Schrör K (2006) Haemostasis and antithrombotic drugs: pharmacology and novel therapeutic approaches. Hamostaseologie 26(2):104–105

    PubMed  Google Scholar 

  7. Catella-Lawson F, Reilly MP, Kapoor SC, Andrew JC, Demarco S, Barbara R, Tournier B et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809–1817

    Article  PubMed  CAS  Google Scholar 

  8. Cohen HW, Crandall JP, Hailpern SM, Billett HH (2008) Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complicat 22(3):224–228

    Article  PubMed  Google Scholar 

  9. Mansour K, Taher AT, Musallan KM, Alams S (2009) Aspirin resistance. Adv Hematol. doi:10.1155/2009/937352

    PubMed  Google Scholar 

  10. Goodman T, Sharma P, Ferro A (2007) The genetics of aspirin resistance. Int J Clin Pract 61:826–834

    Article  PubMed  CAS  Google Scholar 

  11. Tourmousoglou CE, Rokkas CK (2008) Clopidogrel and aspirin in cardiovascular medicine responders or not-current best available evidence. Cardiovasc Hematol Agents Med Chem 6(4):312–322

    Article  PubMed  CAS  Google Scholar 

  12. Papafili A, Hill MR, Brull DJ, Mcanulty RJ, Marshall RP, Humphries SE et al (2008) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22:1631–1636

    Article  Google Scholar 

  13. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST (Trial of Org 10172 in Acute Stroke Treatment). Stroke 24:35–41

    Article  PubMed  Google Scholar 

  14. Munshi A, Sultana S, Kaul S, Pulla Reddy B, Alladi S et al (2008) Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of ischemic stroke in a South Indian population. J Neurol Sci 272:132–135

    Article  PubMed  CAS  Google Scholar 

  15. Kupari M, Hautanen A, Lankinen I, Koskinen P, Virolainen J, Nikkila H et al (1998) Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass and function. Circulation 97:569–575

    Article  PubMed  CAS  Google Scholar 

  16. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230–235

    Article  PubMed  CAS  Google Scholar 

  17. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D et al (1997) Variable platelet response to low dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78:1003–1007

    PubMed  CAS  Google Scholar 

  18. Hankey GJ, Eikebboon JN (2006) Aspirin resistance. Lancet 367:606–617

    Article  PubMed  CAS  Google Scholar 

  19. Sadiq PA, Puri A, Dixit M, Ghatak A, Dwinder SK, Narain VS et al (2005) Profile and prevalence of aspirin resistance in Indian patients with coronary artery disease. Indian Heart J 57:658–661

    PubMed  CAS  Google Scholar 

  20. Goodman T, Ferro A, Sharma P (2008) Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 66(2):222–232

    Article  PubMed  Google Scholar 

  21. Kohsaka S, Volcik KA, Folsom AR, Wu KK, Ballantyne CM, Willerson JT et al (2008) Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2)G −765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 196(2):926–930

    Article  PubMed  CAS  Google Scholar 

  22. Colaizzo D, Fofi L, Tiscia G (2006) The COX-2G/C −765 polymorphism may modulating the occurrence of cerebrovascular ischemia. Blood Coagul Fibrinolysis 17:93–96

    Article  PubMed  CAS  Google Scholar 

  23. Hegener HH, Diehl KA, Kurth T, Gaziano JM, Ridker PM, Zee RY (2006) Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case–control approach. J Thromb Haemost 4(8):1718–1722

    Article  PubMed  CAS  Google Scholar 

  24. Huuskonen KH, Kunnas TA, Tanner MM, Mikkelsson J, Ilveskoski E, Karhunen PJ et al (2008) COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study. Mediators Inflamm 2008:289453

    Article  PubMed  Google Scholar 

  25. Maguire J, Thakkkinskian A, Levi C, Lineze L, Bisset L, Sturm J et al (2010) Impact of COX-2 rs5275 and rs20417 and GP IIIa rs5918 polymorphism on 90 day ischemic stroke functional outcome; A novel finding. J Stroke Cerebrovasc Dis. doi:10.1016/i.jstrokecerebrovasdis.2009.10.011

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Biology, Institute of Genetics and Hospital for Genetic Diseases, Osmania University, Begumpet, Hyderabad, 500016, India

    Vandana Sharma, A. Jyothy & Anjana Munshi

  2. Dr. NTR University of Health Sciences, Vijayawada, Andhra Pradesh, India

    Vandana Sharma

  3. Nizam’s Institute of Medical Sciences, Punjagutta, Hyderabad, 500082, India

    Subhash Kaul

  4. Department of Botany and Microbiology, King Saud University, Riyadh, Saudi Arabia

    Amal Al-Hazzani

  5. Molecular Cancer Biology Research Lab., Department of Food Science and Nutrition, King Saud University, Riyadh, Saudi Arabia

    Ali A. Alshatwi

Authors
  1. Vandana Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Subhash Kaul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amal Al-Hazzani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ali A. Alshatwi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Jyothy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anjana Munshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anjana Munshi.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 14 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, V., Kaul, S., Al-Hazzani, A. et al. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis 35, 95–99 (2013). https://doi.org/10.1007/s11239-012-0777-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-012-0777-8

Keywords

Search

Navigation